PolyPeptide Group AG (XSWX:PPGN) Debt-to-Equity : 0.30 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG Debt-to-Equity?

PolyPeptide Group AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF43.1 Mil. PolyPeptide Group AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF64.1 Mil. PolyPeptide Group AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was CHF359.5 Mil. PolyPeptide Group AG's debt to equity for the quarter that ended in Dec. 2023 was 0.30.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PolyPeptide Group AG's Debt-to-Equity or its related term are showing as below:

XSWX:PPGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.22 Max: 0.3
Current: 0.3

During the past 6 years, the highest Debt-to-Equity Ratio of PolyPeptide Group AG was 0.30. The lowest was 0.04. And the median was 0.22.

XSWX:PPGN's Debt-to-Equity is ranked worse than
50.24% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs XSWX:PPGN: 0.30

PolyPeptide Group AG Debt-to-Equity Historical Data

The historical data trend for PolyPeptide Group AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG Debt-to-Equity Chart

PolyPeptide Group AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.24

0.21

0.04

0.05

0.30

PolyPeptide Group AG Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					0.04	0.05	0.05	0.20	0.30

Competitive Comparison of PolyPeptide Group AG's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPeptide Group AG's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's Debt-to-Equity falls into.

PolyPeptide Group AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PolyPeptide Group AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(43.104	+	64.088)	/	359.524
	=	0.30

PolyPeptide Group AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(43.104	+	64.088)	/	359.524
	=	0.30

PolyPeptide Group AG (XSWX:PPGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PolyPeptide Group AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PolyPeptide Group AG (XSWX:PPGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PPGNz:UK

Address

Neuhofstrasse 24, Baar, Zug, CHE, 6340

Website

https://www.polypeptide.com

PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines